Loading...
Tolvaptan, hyponatremia, and heart failure
Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108793/ https://ncbi.nlm.nih.gov/pubmed/21694950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S7032 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|